New IDEXX RealPCR™ Tests Available [Trade]
IDEXX Reference Laboratories introduces the first of a full menu of tests and profiles using real-time PCR technology for fast, accurate answers to veterinarians’ toughest cases

Westbrook, Maine, June 1, 2007—IDEXX Reference Laboratories, a division of IDEXX Laboratories, Inc. (NASDAQ:IDXX), announced today the availability of new IDEXX RealPCR™ Tests to help veterinary practitioners diagnose their most challenging cases. These new tests, which use real-time PCR (polymerase chain reaction) methodology, were developed by IDEXX’s new Molecular Diagnostics Laboratory team, under the direction of Christian Leutenegger, DrVetMed, PhD, FVH. Veterinary practices now have convenient and affordable access to the accuracy of real-time PCR as part of their routine testing. Results are available in just one to three days.

Feline Upper Respiratory Disease (URD) Panel. This panel detects several organisms that cause a group of common related illnesses. Until now, accurately diagnosing the cause and treating feline URD required multiple tests with varying levels of reliability. The new IDEXX RealPCR panel helps practitioners pinpoint the cause of a feline URD because it detects, in one sample, the five most common organisms that cause URD in cats: feline herpesvirus-1 (FHV-1), feline calicivirus (FCV), Chlamydophila felis (formerly known as Chlamydia psittaci), Mycoplasma felis and Bordetella bronchiseptica. The answers provided by this comprehensive panel can help direct management and treatment of these cats to prevent the spread of infection and lead to a faster recovery and improved prognosis.

Feline Hemotropic Mycoplasma (formerly Haemobartonella) Test. This test can help veterinarians save lives by taking the guesswork out of diagnosing feline anemia. By routinely performing this test on anemic patients, a veterinarian can quickly rule in or rule out feline hemotropic mycoplasmosis (FHM; formerly haemobartonellosis or feline infectious anemia) as the cause of anemia. The test’s fluorescent probe technology is ten times more sensitive than visually inspecting traditional blood smears. In addition to Mycoplasma haemofelis, two additional strains that can be cofactors for anemia or induce anemia by themselves are detected by IDEXX RealPCR testing: Candidatus Mycoplasma haemominutum and Candidatus Mycoplasma turicensis.

With just a one- to three-day turnaround time for IDEXX RealPCR results, practices can more quickly work through their list of differential diagnoses, provide answers to their clients and begin treatment. Compared with traditional PCR tests, the IDEXX RealPCR Tests cost about the same as mainstream diagnostic tests available through IDEXX Reference Laboratories.

The following IDEXX RealPCR panels and tests can be ordered separately, with chemistry/CBC panels, or added to routine laboratory tests from IDEXX Reference Laboratories.

For more information about IDEXX RealPCR panels and standalone tests, call the Internal Medicine Team at IDEXX Reference Laboratories: 1-888-433-9987. Select option 4, then option 2, or visit idexx.com/realpcr.

About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice management systems and pharmaceuticals. IDEXX products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Westbrook, Maine, IDEXX Laboratories employs more than 4,000 people and offers products to customers in over 100 countries.

Note Regarding Forward-Looking Statements
This press release contains statements about the Company’s business prospects and estimates of the Company’s financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management’s expectations. Factors that could cause or contribute to such differences include the following: the Company’s ability to develop, manufacture, introduce and market new products and enhancements to existing products; the Company’s ability to integrate and operate acquired businesses; the effect of government regulation on the Company’s business, including government decisions about whether and when to approve the sale of the Company’s products and decisions regarding labeling, manufacturing and marketing of products; disruptions, shortages or pricing changes that affect the Company’s purchases of products and materials from third parties, including from sole source suppliers; the impact of distributor purchasing decisions on sales of our products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company’s products and services by veterinarians; the Company’s ability to obtain and maintain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; the effects of government regulatory decisions, customer demand, pricing and other factors on the realizability of the Company’s inventories; the Company’s ability to manufacture complex biologic products; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the loss of key employees. A further description of these and other factors can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2006 (1.5 MB), and Form 10-Q for the quarter ended March 31, 2007 (272 KB), in the section captioned "Risk Factors."

This symbol indicates PDF-formatted materials. To view, you may need to download a free copy of Adobe^® Reader^® software.